We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.48% | 103.00 | 102.00 | 104.00 | 103.50 | 103.00 | 103.50 | 66,366 | 15:28:42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
TIDMDXRX
Diaceutics PLC
30 September 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Poster presentation at ESMO
Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will present a poster at the 2019 European Society of Medical Oncology Congress ("ESMO") in Barcelona today. ESMO will run from 27 September - 1 October 2019.
ESMO is the most influential oncology meeting in Europe, in partnership with the EACR (European Association for Cancer Research). The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care.
The Company will present a poster entitled "Known and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries". The Poster focusses on the current next generation sequencing ("NGS") capabilities in solid tumour oncology laboratories to detect unknown gene fusions, and concludes that labs in the EU have not kept up with the technical advances in NGS testing due to a lack of sufficient funding, which may lead to missed opportunities for improved treatment for patients.
The poster can be viewed via this link once it has been presented:
http://www.rns-pdf.londonstockexchange.com/rns/0424O_1-2019-9-29.pdf
Enquiries:
Diaceutics PLC www.diaceutics.com Peter Keeling, Chief Executive via Walbrook PR Officer Philip White, Chief Financial Officer Cenkos Securities plc (Nominated adviser and broker) +44 (0) 20 3861 6630 Callum Davidson / Giles Balleny Michael Johnson (Sales) Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com Anna Dunphy Mob: +44 (0)7876 741 001 Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRACKCDDKBKDPCB
(END) Dow Jones Newswires
September 30, 2019 03:01 ET (07:01 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions